Citations

Clear

1792 citation(s) found for "Stephanie".

Evidence for a Role of NTS2 Receptors in the Modulation of Tonic Pain Sensitivity
Roussy, Geneviève, Dansereau, Marc‐André, Baudisson, Stéphanie, Ezzoubaa, Faouzi, Belleville, Karine, Beaudet, Nicolas , Martínez, Jean , Richelson, Elliott, Sarret, Philippe

Mayo Clinic

Molecular Pain | July 7, 2009 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1186/1744-8069-5-38 | PMID 19580660 Get It

BackgroundCentral neurotensin (NT) administration results in a naloxone-insensitive antinociceptive response in animal models of acute and persistent pain. Both NTS1 and NTS2 receptors were shown to be required for different aspects of NT-induced analgesia. We recently demonstrated that NTS2 receptors were extensively associated with ascending nociceptive pathways, both at the level of the dorsal root ganglia and of the spinal dorsal horn. Then, we found that spinally administered NTS2-selective agonists induced dose-dependent antinociceptive responses in the acute tail-flick test. In the present study, we therefore investigated whether activation of spinal NTS2 receptors suppressed the persistent inflammatory pain symptoms observed after intraplantar injection of formalin.ResultsWe first demonstrated that spinally administered NT and NT69L agonists, which bind to both NTS1 and NTS2 receptors, significantly reduced pain-evoked responses during the inflammatory phase of the formalin test. Accordingly, pretreatment with the NTS2-selective analogs JMV-431 and levocabastine was effective in inhibiting the aversive behaviors induced by formalin. With resolution at the single-cell level, we also found that activation of spinal NTS2 receptors reduced formalin-induced c-fos expression in dorsal horn neurons. However, our results also suggest that NTS2-selective agonists and NTS1/NTS2 mixed compounds differently modulated the early (21–39 min) and late (40–60 min) tonic phase 2 and recruited endogenous pain inhibitory mechanisms integrated at different levels of the central nervous system. Indeed, while non-selective drugs suppressed pain-related behaviors activity in both part of phase 2, intrathecal injection of NTS2-selective agonists was only efficient in reducing pain during the late phase 2. Furthermore, assessment of the stereotypic pain behaviors of lifting, shaking, licking and biting to formalin also revealed that unlike non-discriminative NTS1/NTS2 analogs reversing all nociceptive endpoint behaviors, pure NTS2 agonists specifically inhibited paw lifting, supporting a role of NTS2 in spinal modulation of persistent nociception.ConclusionThe present study provides the first demonstration that activation of NTS2 receptors produces analgesia in the persistent inflammatory pain model of formalin. The dichotomy between these two classes of compounds also indicates that both NTS1 and NTS2 receptors are involved in tonic pain inhibition and implies that these two NT receptors modulate the pain-induced behavioral responses by acting on distinct spinal and/or supraspinal neural circuits. In conclusion, development of NT agonists targeting both NTS1 and NTS2 receptors could be useful for chronic pain management.
P4‐047: Use of a wild‐type tauopathy model to generate a novel Alzheimer model
Adams, Stephanie J. , McBride, Melinda, Crook, Richard , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2009.04.917 Get It

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer
Karp, Daniel D. , Paz‐Ares, Luis , Haluska, Paul , Garland, Linda L., Cardenal, Felipe, Blakely, L. Johnetta , Eisenberg, Peter D., Langer, Corey J. , Blumenschein, George R. , Novello, Silvia , Johnson, Faye M. , Green, Stephanie , Gualberto, Antonio

Mayo Clinic

Journal of Clinical Oncology | April 21, 2009 | Volume: 27 | Issue: 15 | Pages: 2516-2522

10.1200/jco.2008.19.9331 | PMID 19380445 Get It

Purpose We conducted a phase II study of combination of the anti–insulin-like growth factor 1 receptor antibody CP-751,871 with paclitaxel and carboplatin (PCI) in advanced treatment-naïve non–small-cell lung cancer (NSCLC). Patients and Methods Patients were randomly assigned (2:1) to paclitaxel 200 mg/m2, carboplatin (area under the plasma concentration-time curve of 6), and CP-751,871 10 to 20 mg/kg (PCI10, PCI20) or paclitaxel and carboplatin alone (PC) every 3 weeks for up to six cycles. PCI10-20 patients could continue CP-751,871 (figitumumab) treatment after chemotherapy discontinuation. Patients treated with PC experiencing disease progression were eligible to receive CP-751,871 at investigator's discretion. An additional nonrandomized single-arm cohort of 30 patients with nonadenocarcinoma tumor histology receiving PCI20 was enrolled on completion of the randomized study. Results A total of 156 patients were enrolled onto the randomized portion of the study. Safety and efficacy information are available for 151 patients (98 patients treated with PCI and 53 patients treated with PC). Forty-eight patients treated with PCI received PCI10 and 50 patients received PCI20 in two sequential stages. Twenty of 53 patients treated with PC received CP-751,871 after disease progression. PCI was well tolerated. Fifty-four percent of patients treated with PCI and 42% of patients treated with PC had objective responses. Sixteen of 23 patients assessable for efficacy in the nonrandomized single-arm extension cohort also responded to treatment. Of note, 14 of 18 randomly assigned and 11 of 14 nonrandomly assigned patients treated with PCI with squamous cell carcinoma histology had response to treatment, including nine objective responses in bulky disease. Responses were also observed in two patients with squamous histology receiving CP-751,871 on PC discontinuation. PCI20/PC hazard ratio for progression-free survival was 0.8 to 0.56, according to censorship. Conclusion These data suggest that PCI20 is safe and effective in patients with NSCLC.
Symptom Check: Is It GERD?
Sveen, Stephanie

Mayo Clinic

The Journal of Continuing Education in Nursing | April 20, 2009 | Volume: 40 | Issue: 3 | Pages: 103-104

10.3928/00220124-20090301-04 | PMID 19326815 Get It

Despite the vast number of individuals living with gastroesophageal reflux disease (GERD), establishing a diagnosis can be difficult. Detailed patient history and symptom review are critical. Nurses can play an integral role in gathering information that may lead to a definitive diagnosis. In addition to the classic symptoms of GERD—acid reflux and heartburn—several atypical conditions may also be present. Understanding the diverse and subtle nature of presenting symptoms can assist in establishing a GERD diagnosis. This column examines the atypical presentations of GERD, including laryngopharyngeal symptoms, chronic cough, asthma, and dental erosions. J Contin Educ Nurs 2009;40(3):103–104.
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Reiman, Eric M. , Chen, Kewei , Bandy, Daniel, Yu, Meixiang , Lee, Wendy , Ayutyanont, Napatkamon , Keppler, Jennifer, Reeder, Stephanie, Alexander, Gene E. , Klunk, William E. , Mathis, Chester A. , Price, Julie C. , Aizenstein, Howard , DeKosky, Steven T. , Caselli, Richard J. , Liu, Xiaofen , Reeder, Stephanie, Langbaum, Jessica B. S.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 3, 2009 | Volume: 106 | Issue: 16 | Pages: 6820-6825

10.1073/pnas.0900345106 | PMID 19346482 Get It

Fibrillar amyloid-beta (Aβ) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Inwards, David J. , Spies, Stewart, Wiseman, Gregory A., Patton, David R. , Erwin, William D. , Rademaker, Alfred , Weitner, Bing Bing, Williams, Stephanie , Tallman, Martin S. , Micallef, Ivana N. , Mehta, Jayesh, Evens, Andrew M. , Zimmer, Michael, Molina, Arturo , Gordon, Leo I. , Winter, Jane N. , Singhal, Seema , White, Christine A. , Gordon, Leo I , Evens, Andrew M , Patton, David R

Mayo Clinic

Journal of Clinical Oncology | March 3, 2009 | Volume: 27 | Issue: 10 | Pages: 1653-1659

10.1200/jco.2008.19.2245 | PMID 19255322 Get It

Purpose To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 (90Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation. Patients and Methods Eligible patients had relapsed or refractory CD20+ non-Hodgkin's lymphoma (NHL). Individualized 90Y activities were based on dosimetry and were calculated to deliver cohort-defined RAD (1 to 17 Gy) to critical organs with three to six patients per cohort. The therapeutic dose of 90Y ibritumomab tiuxetan was followed by high-dose BEAM and autologous transplantation. Results Forty-four patients were treated. Thirty percent of patients had achieved less than a partial remission to their most recent therapy and would not have been eligible for autologous transplantation at most centers. The toxicity profile was similar to that associated with high-dose BEAM chemotherapy. Two dose-limiting toxicities occurred at the 17 Gy dose level, which made 15 Gy the recommended maximum-tolerated RAD. Although eight patients received at least twice the conventional dose of 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have resulted in a wide range of RAD; nearly 25% of patient cases would have received 17 Gy or more, and many would have received less than 10 Gy. With a median follow-up of 33 months for all patients, the estimated 3-year progression-free and overall survivals were 43% and 60%, respectively. Conclusion Dose-escalated 90Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy. Careful dosimetry is required to avoid toxicity and undertreatment.
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
Cooper, David S. , Doherty, Gerard M. , Haugen, Bryan R. , Kloos, Richard T. , Mandel, Susan J., Mazzaferri, Ernest L. , McIver, Bryan, Sherman, Steven I. , Tuttle, R. Michael , Lee, Stephanie L. , Kloos, Richard T , Sherman, Steven I

Mayo Clinic

Thyroid | February 25, 2009 | Volume: 16 | Issue: 2 | Pages: 109-142

10.1089/thy.2006.16.109 | PMID 16420177 Get It

Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene
Carlson, Stephanie K., Classic, Kelly, Hadac, Elizabeth M., Dingli, David , Bender, Claire E., Kemp, Bradley J. , Russell, Stephen J. , Dingli, David

Mayo Clinic

American Journal of Roentgenology | December 19, 2008 | Volume: 192 | Issue: 1 | Pages: 279-287

10.2214/ajr.08.1205 | PMID 19098211 Get It

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer
Hines, Stephanie L., Mincey, Betty A., Sloan, Jeff A. , Thomas, Sachdev , Chottiner, Elaine G., Loprinzi, Charles L. , Carlson, Mark D., Atherton, Pamela J., Salim, Muhammad , Perez, Edith A. , Atherton, Philip J. , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

Journal of Clinical Oncology | December 16, 2008 | Volume: 27 | Issue: 7 | Pages: 1047-1053

10.1200/jco.2008.19.1783 | PMID 19075260 Get It

Purpose Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer. Patients and Methods Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the start of chemotherapy. Most chemotherapy regimens included anthracyclines, taxanes, or cyclophosphamide. Bone mineral density (BMD) was measured at baseline and 1 year. The primary end point was the change in lumbar spine (LS) BMD from baseline to 1 year. Results A total of 216 women enrolled; 170 women provided BMD data at 1 year. There was no difference in the mean change or percent change in LS BMD between groups, with a loss of 4.3% in the risedronate arm and 5.4% for placebo at 1 year (P = .18). Loss of BMD at the femoral neck and total hip were also similar between treatment groups. Risedronate was well tolerated, with no significant differences in adverse events compared with placebo, except that arthralgias and chest pain were worse in those receiving the placebos. Conclusion Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer.